The HCRT1 (Hypocretin/Orexin 1) gene encodes the orexin-A neuropeptide, a critical regulator of arousal, wakefulness, and energy homeostasis. Formerly known as hypocretin-1, orexin-A is produced by a small population of neurons in the lateral hypothalamus and plays essential roles in sleep-wake regulation, reward processing, and metabolic function.
The HCRT gene encodes a pre-pro-orexin precursor that is cleaved to produce two neuropeptides:
These peptides bind to two G-protein coupled receptors:
Orexin neurons form a critical wake-promoting system in the brain. These neurons are active during wakefulness, particularly during active exploration and reward-seeking behavior, and become silent during sleep. The orexin system helps maintain arousal, prevent sleep onset, and regulate sleep-wake transitions[1:2][3].
Orexin neurons integrate metabolic signals (leptin, ghrelin, glucose) to regulate feeding behavior and energy expenditure. Activation of orexin neurons promotes food-seeking behavior and increases metabolic rate[4].
The orexin system projects to reward-related brain regions (VTA, NAc, lateral septum) and modulates dopamine-mediated reward processing. Orexin is involved in drug-seeking behavior and addiction[5].
Sleep disorders, particularly REM sleep behavior disorder (RBD), are common early markers of Parkinson's disease (PD). Remarkably, orexin neuron loss has been documented in PD patients, with studies showing a 40-50% reduction in orexin-producing neurons in the lateral hypothalamus[6]. This loss correlates with:
The degeneration of orexin neurons may contribute to the sleep disturbances and autonomic dysfunction seen in PD[6:1][7].
Orexin dysregulation has been implicated in the sleep disturbances characteristic of Alzheimer's disease (AD). Elevated orexin-A levels have been found in the CSF of AD patients, potentially reflecting compensatory mechanisms or circadian rhythm disruption[8]. Sleep fragmentation and altered orexin signaling may:
MSA patients show significant orexin neuron loss, even more pronounced than in PD. This loss correlates with autonomic dysfunction and disease severity[9].
Orexin neurons are localized primarily in:
These neurons project widely to:
The orexin system represents a therapeutic target for neurodegenerative diseases:
Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007. ↩︎ ↩︎ ↩︎ ↩︎
Chemelli RM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999. ↩︎ ↩︎
Saper CB, Fuller PM, Pedersen NP. Sleep state switching. Neuron. 2010. ↩︎
Willie JT, et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci. 2001. ↩︎
Aston-Jones G, et al. Orexin/hypocretin and reward: role of the orexin system in cocaine-seeking. J Addict Res Ther. 2011. ↩︎
Fronczek R, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain. 2007. ↩︎ ↩︎
Thannickal TC, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000. ↩︎ ↩︎
Liguori C, et al. Orexinergic system dysregulation in Alzheimer's disease: a new therapeutic target? J Alzheimers Dis. J Alzheimers Dis. 2020. ↩︎ ↩︎ ↩︎
Gilman S, et al. Reduction of orexin (hypocretin) neurons in multiple system atrophy. Neurology. 2010. ↩︎
Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011. ↩︎
Kuszak AJ, et al. Orexin-A protects against amyloid-beta-induced oxidative stress and mitochondrial dysfunction in neuronal cells. J Mol Neurosci. 2019. ↩︎
Kang JH, et al. Orexin receptor antagonism improves sleep and reduces amyloid-beta in a mouse model of Alzheimer's disease. J Neurosci. 2016. ↩︎